Order Article Reprints

Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, et al. Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers. 2021; 13(19):4884. https://doi.org/10.3390/cancers13194884

Harbeck, Nadia, Raquel von Schumann, Ronald Ernest Kates, Michael Braun, Sherko Kuemmel, Claudia Schumacher, Jochem Potenberg, Wolfram Malter, Doris Augustin, Bahriye Aktas, and et al. 2021. "Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer" Cancers 13, no. 19: 4884. https://doi.org/10.3390/cancers13194884

Harbeck, N., von Schumann, R., Kates, R. E., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Malter, W., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Grischke, E.-M., Biehl, C., Liedtke, C., De Haas, S. L., Deurloo, R., Wuerstlein, R., Kreipe, H. H., & Gluz, O. (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers, 13(19), 4884. https://doi.org/10.3390/cancers13194884